Kinetics of serum antibodies in response to infection with *Yersinia enterocolitica*

I. Vaitkeviciute, P.F.M. Teunis, W. van Pelt and K.A. Krogfelt

Abstract

Information on the kinetics of the serum antibody response to infection with *Yersinia enterocolitica* is essential to allow the estimation and comparison of seroconversion rates in a diversity of pools of cross-sectional serum antibody measurements. Data from 94 patients with acute enteritis caused by *Yersinia* infection were used. The follow-up period for the longitudinal study was 36 months, addressed by questionnaire. An indirect enzyme-linked immunosorbent assay method was adapted to determine the concentration of antibodies against *Y. enterocolitica* in human sera. A mathematical within-host model was used to describe the interaction between pathogen and immune system and the waning of immunity after clearing of the pathogen. All observed antibodies (IgG, IgM, IgA) reached peak levels shortly after infection and then decayed slowly indicating that the median levels decreased only little during the observation period. Estimated maximum peak antibody levels were highest in IgG. Seroresponse curves of all antibodies showed large individual variation between patients. There was no apparent pattern of variation with age, nor any notable difference between genders. Estimated half-times were very long for all antibodies, and their posterior distributions were highly skewed. IgA appeared to have the most persistent antibody response, compared with IgG and IgM. Median peak levels of all three antibodies were similar. There was no significance found between peak antibody levels and severity of symptoms of gastrointestinal infection and severity of joint pain. Our findings allow the use of cross-sectional serum antibody measurements as biomarkers, to estimate seroconversion rates. Such seroconversion estimates include asymptomatic seroconversions, thereby avoiding under-reporting, and allows the comparison of infection pressures among countries, independent of their healthcare and surveillance systems.

Introduction

*Yersinia enterocolitica* is an enteric pathogen, which may cause acute gastrointestinal disease in humans. *Y. enterocolitica* is widely distributed in aquatic and animal reservoirs, with swine serving as a major reservoir for human pathogenic strains. In the gastrointestinal tract, *Y. enterocolitica* can cause acute enteritis, enterocolitis, mesenteric lymphadenitis and terminal ileitis [1].

Bacteria of the genus *Yersinia* are a common cause of gastroenteritis in most of the European Union/European Economic Area (EU/EEA) countries [2]. *Y. enterocolitica* is the most common *Yersinia* species reported in human cases (more than 96% of all confirmed cases in 2011, similar tendency was seen in previous years). Despite the fact that numbers of reported cases have decreased in the period 2008–2012, *yersiniosis* is still the third most commonly reported bacterial zoonosis in humans and a frequently reported gastrointestinal disease in Europe [2].

Surveillance of *yersiniosis* is important because it helps to monitor incidence trends, to identify groups with increased risks and to indicate possible outbreaks [3]. According to the European Centre for Disease Control and Prevention (ECDC) epidemiological report, 6548 confirmed cases of *yersiniosis* were reported by EU/EEA countries, in 2012. In the same year, the annual number of episodes of clinical gastroenteritis caused by *Yersinia* in Denmark is estimated to be 271 [2]. However, not all the countries in Europe are reporting cases of disease – the Netherlands stopped *Yersinia* surveillance in 1996 [4].

Disease surveillance and notification systems are affected by under-reporting which can lead to underestimation of incidence of disease, and the related burden of morbidity and mortality. In particular, surveillance systems tend to miss cases at two different levels of the surveillance pyramid: at the community level, where not all people suffering from disease seek healthcare, and at the healthcare level – under-reporting symptomatic cases that have sought medical assistance [5].
Serological methods are important as an additional source of information for infectious disease epidemiology [6–7]. Infection with a pathogenic organism usually results in the appearance of antibodies that can be detected in a blood sample. Therefore, serum antibody concentrations are important to study the occurrence of infections at the population level [8]. Furthermore, determination of specific antibodies can be important in the final diagnosis of sequelae like reactive arthritis [9–11]. A large community-based study was performed to establish the extent to which patients with gastroenteritis in the population sought medical advice and had a stool culture performed. It was shown that the ratio between cases and the numbers who visited their general practitioner varied from 1 to 2.1 for Salmonella, Shigella and Campylobacter species, whereas it reached 11.7 for Yersinia, indicating that for every case presenting to GP there were around 12 additional Yersinia infection cases in the community [12].

The present paper describes a longitudinal study of the serum antibody response to infection with Y. enterocolitica, to provide essential information on the kinetics of serum antibodies. These allow the use of cross-sectional serum antibody measurements as biomarkers, to estimate seroconversion rates (or seroincidences) [12]. Such seroincidence estimates include asymptomatic seroconversions, thereby avoiding under-reporting mentioned above, and allows the comparison of infection pressures among countries, independent of their healthcare and surveillance systems. As far as authors know, there are no published seroepidemiological studies into Y. enterocolitica.

Methods and materials

Study population

Data from 94 patients with acute enteritis caused by Yersinia infection were used. Participants were recruited from the Danish Registry of Bacterial Enteropathogens (DRBE) after a stool culture had confirmed bacterial gastroenteritis caused by Yersinia. The Statens Serum Institut (SSI) in Copenhagen performs ongoing surveillance of infectious diseases in Denmark, and information on patient identity, referring doctor and results of cultures is stored in the database.

The follow-up period for the longitudinal study was 36 months. Study started on 7 January 2002 and the last sample was taken on 15 December 2004. There were 38 (40.4%) males and 56 (59.6%) females participating in the study. The median age was 43 years. All patients were asked to deliver a blood sample 1 month after the onset of diarrhoea, and subsequently provide samples at 3, 6 and 36 months. Seventy-seven patients delivered the first blood sample, 39 (51%) delivered the second blood sample, 60 (80%) delivered the third sample and 44 (57%) delivered the first blood sample, 39 (51%) delivered the second blood sample, 60 (80%) delivered the third sample and 44 (57%) delivered the fourth sample.

We joined the serology database with additional data from a related study [11] where all patients from the Yersinia study, who were more than 18 years old (and gave informed consent to participate), were included and filled in a questionnaire. This added self-reported information about the severity of symptoms of gastrointestinal infection (GI) and severity of joint pain (JP). Based on given information, patients were divided into three severity groups (mild, moderate or severe) for GI and JP separately. Also, severity of JP was examined by asking participants to provide an overall evaluation about their JP on the visual analogue scale (VAS) varying from 0 (‘no pain’) to 100 (‘worst imaginable pain’).

The Ethical Scientific Committee for Copenhagen approved the study (KF 01–300/00). The study was evaluated by the General Practitioners Research Council who encouraged members of the Danish Society for General Practitioners to participate in the study.

Serum samples

An indirect enzyme-linked immunosorbent assay (ELISA) method was developed for the determination of the concentration of antibodies against Y. enterocolitica O:3 in human sera. The ELISA procedure was performed in microtiter wells (Nunc-Immuno™ plates Polysorp™ F96, Sigma-Aldrich St Louis, MO, USA) and the analysis itself was automatized at a BioMek® 2000 robot (Beckman Coulter Inc., Atlanta, GA, USA). Antigen (Yersinia O:3 BN50, Danish Institute for Food and Veterinary Research, Lyngby, DK) diluted 1 in 1000 in 100 µl 'coating-buffer' (carbonate-buffer at pH 9.60 containing 2 ml phenol red per litre) per well was used for an overnight coating at 4 °C. After a wash ('wash-buffer', i.e. phosphate-buffered saline (PBS) at pH 7.4 containing 1 ml Tween®20 per litre, was added at 250 µl per well and subsequently evacuated, four successive cycles were used), the wells were blocked by incubation with 250 µl 'wash-buffer' per well for 30 min at room temperature. The wells were subsequently washed and 100 µl of serum diluted 400 times in 'dilution-buffer' (PBS at pH 7.4 containing 1 ml Tween®20 per litre and 2 ml phenol red per litre) was added per well in duplicates and incubated in room temperature for 30 min. After a wash, 100 µl of dilutions made in 'dilution-buffer' of horseradish peroxidase conjugated rabbit anti-human IgG, IgM or IgA (Dako, cat.no. P0214, P0215 and P0216) was added per well (anti-IgG diluted 2500 times, anti-IgM diluted 1000 times and anti-IgA diluted 500 times) and incubated at 30 minutes at room temperature. One hundred microlitres of 1 M H2SO4 was added per well, and the optical density at 630 nm was finally determined. Each serum was analysed for the presence of IgG-, IgM- and IgA-anti-LPS antibodies.

Clinical validation of the test including sensitivity and specificity has been published [13]. Day-to-day variations were minimised by including a dilution series of a standard and a positive (X1) and a negative control (X0) at each analysis and expressing antibody levels (X) as a fraction of the range between positive and negative controls.

\[ Y = \frac{X - X_0}{X_1 - X_0} \]

In order to avoid measurement errors, all tests were performed in duplicates and only accepted if the coefficient of variation was below 5%.

Model analyses

A mathematical within-host model was used to describe the interaction between pathogen and immune system and the waning of immunity after clearing of the pathogen. Upon infection with a certain dose (initial inoculum), numbers of bacteria in the host start increasing exponentially. At the same time, circulating antigen stimulates antibody-producing cells to generate new antibodies that inactivate (possibly indirectly) invading bacteria. Within a brief period, pathogen growth is stopped, and numbers of bacteria start to decline to zero. As soon as all bacteria have been killed off, antibody growth stops and a period of waning immunity begins, with antibody levels slowly declining towards zero. At the time of infection, serum antibody levels in the host
are at (non-zero) baseline, indicating immunity due to antibodies remaining from the seroresponse to a previous infection.

The within-host model of bacterial infection may be fitted to serological data in a mixed (two-level) model Bayesian statistical framework. This allows incorporating the variation in seroresponses among individual patients, a prominent and common property of longitudinal serological data. Here, each individual has their own seroresponse curve, while the variation among patients is modelled by assigning all model parameters a (joint) probability distribution, representing the variation among the members of the sampled population.

A detailed description of the model, including its mathematical properties and details of the statistical framework and fitting procedures, has been published [14]. As in the cited paper, the model was run in [AGS] [15], from the statistical platform ‘R’ [16], using the library rjags [17]. Results show either parameter estimates for individual patients (Figs 3–5) or predicted characteristics, calculated using ‘group’-level parameter samples (Figs 1 and 2 and Tables 1 and 2). While analysing follow-up data of decaying antibody levels, there is always a possibility that patients are re-infected during their follow-up period. Including such data would lead to incorrect estimates of peak antibody levels and decay rates. In order to avoid such events of reinfection, we defined a likely re-infection as a more than twofold increase (relative to the previous measurement), unless the second antibody level was 0.05 (AU) or smaller. Data from subjects where such an increase occurred in any antibody type (IgG, IgM, IgA) were deleted, from the point where the increase occurred.

All additional calculations and tabulations were done using ‘R’ [16].

**Results**

Among the serum samples from 94 patients with a culture-proven *Y. enterocolitica* O:3 infection, a total of 220 sera were analysed by the ELISA method to determine the antibody levels. Observed antibody (IgG, IgM, IgA) decay profiles of all patients are presented in Fig. 1 together with the time course of quantiles (2.5, 0.5, 0.975) of predicted antibody levels. All three antibodies reached peak levels shortly after infection (symptom onset) and then decayed slowly, so that the median levels decreased only little during the observation period (approximately 3 years). Estimated maximum peak antibody levels were highest in IgG, and somewhat lower in IgM and IgA, though the estimated median and mean peak levels did not differ much (Table 1). However, the seroresponse curves of all antibodies showed large individual variation between patients, and some individuals had high values all over the follow-up period, while others remained at low levels (Fig. 1).

Figure 2 illustrates the population estimates of predicted response characteristics – time to peak, peak antibody level and half-time of antibody decay, for all three antibodies. Figure 3 shows the estimates of individual serum antibody peak levels by age, for male and female patients. There is no apparent pattern of variation over age, nor any notable difference between genders.

---

**Fig. 1.** Time course (in days) of the antibody level $y$. The model output is shown as predicted median and 95% range. Also shown are observed antibody levels of 94 patients (multiple observations of each individual connected).

**Fig. 2.** Box plots of predicted response characteristics – time to peak, peak time and half time – of antibody groups. Box plot shows minimum and maximum values in sample, lower quartile, median and upper quartile.

**Fig. 3.** Time to peak (days) of antibody IgG, IgM, IgA. The model output is shown as predicted median and 95% range. Also shown are observed antibody levels of 94 patients (multiple observations of each individual connected).
Table 1 summarises the estimates of the seroresponse characteristics – duration of infection (in days), peak antibody level (OD units) and half-time of antibody decay (in days). The mean, median and 95% ranges are given. Estimated half-times were very long for all antibodies, and their posterior distributions were highly skewed (as indicated by the means>>medians). This may reflect difficulties in estimating antibody decay because antibody levels tend to decrease little over the observation period.

Somewhat surprisingly, IgA appeared to have the most persistent antibody response, followed by IgG with only slightly shorter half-time and IgM with almost two times shorter duration than IgA. Note, however, the high uncertainty in these estimates (95% ranges). Median peak levels of all three antibodies were similar.

Additional data on severity of symptoms were available from a previously published study [11]. Using these data, we have checked possible relations between peak antibody levels and severity (mild, moderate, severe) of gastrointestinal symptoms. Results are shown in Fig. 4. No significant association could be established between peak antibody levels and severity of symptoms (Kruskal–Wallis rank-sum test: data not shown). As estimates of time to peak and half-time of antibody decay were much more uncertain than peak-level estimates, only the latter was considered here. We also tested whether peak antibody levels showed a relation with severity of JP (mild, moderate, severe). Although the peak antibody levels of patients with most severe JPs seemed highest, particularly in IgM and IgA antibodies, there was no significant effect found after testing (data not shown, see Fig. 5).

Discussion

A group of 94 patients with confirmed *Y. enterocolitica* infection were followed up for around 3 years and blood samples were tested for the presence of specific *Yersinia* antibodies (IgG, IgM, IgA). In observing the antibody decay profiles, considerable individual variation can be seen. Similar studies of *Salmonella* and *Campylobacter* [18, 19] showed a similar degree of individual variation.

Within the study population, no association was found between seroresponse characteristics and age or gender. A previous study of antibody responses to *Campylobacter* infection showed that IgM was highest among the youngest patients – in 10–25 years age group (*P* = 0.0001) [19]. Young age dependency...
was also found for IgM response after the infection by *Salmonella* serotype Enteritidis [18]. The present study did not include small children, but a similar association may exist in *Yersinia* infection. This may have clinical relevance because the highest incidence of laboratory-confirmed cases of *Yersinia* spp. infection in the Netherlands was found among the youngest children (0–4 years) and decreased with increasing age [4]. Epidemiological data from Denmark show that before 2008, the majority of persons contracting *Yersinia* enteritis were between 1 and 4 years of age, but since then, the distribution has changed dramatically with the dominating group between 45 and 54 years of age (unpublished data).

We were unable to establish a relation between strength of the seroresponse (peak antibody levels) and severity of symptoms, neither for gastroenteric illness, nor for JPs.

There can be a potential bias affecting the results between peak time levels of different antibodies and severity groups for GI and JP. First, it is possible that the participants cannot remember information or remember incorrectly in self-reported questions and it can cause recall bias – in questions about JP or GI. Second, it is possible that persons with severe symptoms are less likely to forget the intensity of pain compared with those who had mild symptoms, which can misrepresent the strength of association. Third, it cannot be excluded that bias may also have occurred in later evaluation of severity groups based on questionnaires. As stated in a previous study [11], from which we used additional data to check the relation with GI and JP, there are no generally accepted standards existing to classify gastroenteritis and JP into mild, moderate or severe. An arbitrary set of criteria was developed by those authors and applied to the study population.

The present results quantify the seroresponse to infection with *Y. enterocolitica*, including variation in seroresponse characteristics among individual subjects. The predicted characteristics – time to peak, peak level and antibody decay rates – may be used in biomarker studies of seroconversion rates. Given the seroresponse of a population, a cross-sectional sample of observed serum antibody levels may be interpreted as a ‘snapshot’ observation of decaying antibody levels, with higher levels indicating more frequent (more recent) infection [8, 14]. Such studies have been demonstrated to provide useful information about the infection pressure of enteric (and other) pathogens, including asymptomatic (or mildly symptomatic, not notified) infections [20, 21]. Population data on *Yersinia* seroprevalence have not been

| Variable | Interpretation | Unit | Mean | Median | 95% range |
|----------|----------------|------|------|--------|-----------|
| **IgG**  |                |      |      |        |           |
| $t_1$    | Duration of infection | Days | 3.930| 1.360  | 0.0113–22.80 |
| $y_1$    | Peak antibody level | OD   | 0.892| 0.292  | 0.0697–4.20 |
| $T_{1/2}$| Half-time antibody decay | Days | $2.40 \times 10^2$ | 883.0 | 4.650–8.15 $\times 10^5$ |
| **IgM**  |                |      |      |        |           |
| $t_1$    | Duration of infection | Days | 2.270| 0.955  | 3.13 $\times 10^{-5}$–13.40 |
| $y_1$    | Peak antibody level | OD   | 0.670| 0.377  | 0.143–2.620 |
| $T_{1/2}$| Half-time antibody decay | Days | $3.29 \times 10^4$ | 968.0 | 12.00–2.02 $\times 10^5$ |
| **IgA**  |                |      |      |        |           |
| $t_1$    | Duration of infection | Days | 4.510| 1.760  | 7.60 $\times 10^{-5}$–29.20 |
| $y_1$    | Peak antibody level | OD   | 7.080| 0.206  | 0.0333–1.740 |
| $T_{1/2}$| Half-time antibody decay | Days | $2.00 \times 10^{10}$ | $2.26 \times 10^3$ | 8.590–6.05 $\times 10^7$ |

**Fig. 5.** Box plots with different antibody levels for different joint pain (JP) groups. Box plot shows minimum and maximum values in sample, lower quartile, median and upper quartile. There was no significant association found.
Table 2. Estimates of the model parameters and $y_0$ for different antibodies (IgG, IgM, IgA)

| IGA: Variable | Interpretation | Unit | Mean | Median | 95% range |
|---------------|----------------|------|------|--------|-----------|
| $\mu_0$       | Pathogen growth rate | 1/day | 2.27e+01 | -1.02e+00 | -1.87e+02 | 7.03e+02 |
| $\mu_1$       | Antibody growth rate  | 1/day | 4.25e+01 | 4.99e-01  | 4.43e-02  | 3.12e+02 |
| $c_0$         | Pathogen elimination rate/dose | 1/day | 3.86e+03 | 4.82e-01  | 1.99e-05  | 3.61e+04 |
| $w$           | Antibody decay rate   | 1/day | 4.76e-01 | 3.24e-04  | 1.21e-08  | 1.97e-01 |
| $y_0$         | Initial antibody level | IU/ml | 6.19e-02 | 4.14e-02  | 1.00e-02  | 1.61e-01 |

| IgG: Variable | Interpretation | Unit | Mean | Median | 95% range |
|---------------|----------------|------|------|--------|-----------|
| $\mu_0$       | Pathogen growth rate | 1/day | 1.72e+02 | -3.89e-03 | -3.94e+02 | 1.83e+02 |
| $\mu_1$       | Antibody growth rate  | 1/day | 1.07e+01 | 1.25e+00  | 2.18e-02  | 2.53e+01 |
| $c_0$         | Pathogen elimination rate/dose | 1/day | 1.36e+03 | 3.78e+00  | 7.88e-04  | 5.67e+02 |
| $w$           | Antibody decay rate   | 1/day | 8.54e-02 | 8.31e-04  | 8.74e-07  | 2.55e-01 |
| $y_0$         | Initial antibody level | IU/ml | 7.04e-02 | 2.92e-02  | 9.79e-03  | 2.94e-01 |

| IgM: Variable | Interpretation | Unit | Mean | Median | 95% range |
|---------------|----------------|------|------|--------|-----------|
| $\mu_0$       | Pathogen growth rate | 1/day | -4.09e-02 | -1.13e+00 | -4.42e+03 | 7.00e+00 |
| $\mu_1$       | Antibody growth rate  | 1/day | 5.03e+01 | 2.18e+00  | 1.25e-01  | 5.10e+02 |
| $c_0$         | Pathogen elimination rate/dose | 1/day | 1.32e+01 | 7.01e-01  | 2.85e-03  | 1.00e+02 |
| $w$           | Antibody decay rate   | 1/day | 1.46e-02 | 7.40e-04  | 3.50e-06  | 6.62e-02 |
| $y_0$         | Initial antibody level | IU/ml | 6.41e-02 | 6.73e-02  | 2.82e-02  | 1.03e-01 |

Conducted, to date. Yet, they are relevant when studying burden of disease on uniform material and avoiding bias from culturing methodology.

The estimated seroresponse characteristics in this study have considerable uncertainty, due to the limited size of the study with 94 patients and the small number of samples per person (79 with a first sample, 37 with a second sample, 52 with a third sample and 37 with a fourth sample). The difficulties in estimating antibody decay profiles also may be taken as an indication of the follow-up period that is short compared to the persistence of the antibodies detected in this study (fourth sample taken between 353 and 1053 days post-symptom onset while the order of magnitude of the estimated half-time is thousands of days).

Author ORCIDs. P.F.M. Teunis, 0000-0003-1904-6044.

Acknowledgements. The authors thank Peter Schiellerup for collecting the samples and Serological Laboratory for their contribution.

References
1. Bottone EJ (1997) Yersinia enterocolitica: the charisma continues. Clinical Microbiology Reviews 10, 257–276. Available at http://cmr.asm.org/content/10/2/257.long.
2. European Centre for Disease Prevention and Control (2014). Annual Epidemiological Report 2014–Food- and Waterborne Diseases and Zoonoses. Stockholm: ECDC. Available at http://www.ecdc.europa.eu/en/publications/Publications/food-waterborne-diseases-annual-epidemiological-report-2014.pdf.
3. Ternhag A et al. (2004) Basic Surveillance Network, a European database for surveillance data of infectious diseases. Euro Surveillance 9, 472. Available at http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=472.
4. Van Pet W et al. (2003) Laboratory surveillance of bacterial gastroenteric pathogens in The Netherlands, 1991–2001. Epidemiology and Infection 130, 431–441. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2869979/pdf/12825727.pdf.
5. Gibbons CL et al. (2014) Measuring underreporting and underascertainment in infectious diseases datasets: a comparison of methods. BMC Public Health 14, 17. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015599/.
6. Bottone EJ and Sheehan DJ (1983) Yersinia enterocolitica: guidelines for serologic diagnosis of human infections. Reviews of Infectious Diseases 5, 898–906.
7. Marks MI et al. (1980) Yersinia enterocolitica gastroenteritis: a prospective study of clinical, bacteriologic, and epidemiologic features. The Journal of Pediatrics 96, 26–31.
8. Teunis PFM et al. (2012) Biomarker dynamics: estimating infection rates from serological data. Statistics in Medicine 31, 2240–2248.
9. Granfors K et al. (1989) Yersinia antigens in synovial-fluid cells from patients with reactive arthritis. The New England Journal of Medicine 320, 216–221. Available at http://www.nejm.org.proxy1-bib.sdu.dk/doi/full/10.1056/NEJM198901263200404#t=articleTop.
10. Granfors K et al. (1980) Persistence of IgG, IgM and IgA antibodies to Yersinia in Yersinia arthritis. The Journal of Infectious Diseases 141, 424–429. Available at http://www.jstor.org.proxy1-bib.sdu.dk/stable/30081723?seq=1.
11. Schiellerup P et al. (2008) A comparison of self-reported joint symptoms following infection with different enteric pathogens: effect of HLA-B27. The Journal of Rheumatology 35, 3.
12. Wheeler JG et al. (1999) Study of infectious intestinal disease in England: rates in the community, presenting to general practice, and reported to national surveillance. British Medical Journal 318, 1046. Available at http://www.bmj.com/content/318/7190/1046.long.
13. Dalby T et al. (2017) Development of an LPS-based ELISA for diagnosis of Yersinia enterocolitica O:3 infections in Danish patients: a follow-up study. BMC Microbiology 17, 125.
14. Graaf WF et al. (2014) A two-phase within-host model for immune response and its application to serological profiles of pertussis. *Epidemics* 9, 1–7.
15. Plummer M (2003) JAGS: A program for analysis of Bayesian graphical models using Gibbs sampling. In: Proceedings of the 3rd International Workshop on Distributed Statistical Computing (DSC 2003), Vienna, Austria.1–10.
16. R core team (2015) *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R foundation for statistical computing.
17. Plummer M (2015) *rjags*: Bayesian graphical models using MCMC. R package, version 3-15.
18. Strid MA et al. (2007) Kinetics of the human antibody response against *Salmonella enterica* serovars enteritidis and typhimurium determined by lipopolysaccharide enzyme-linked immunosorbent assay. *Clinical and Vaccine Immunology* 14, 741–747. Available at http://cvi.asm.org/content/14/6/741.long
19. Strid MA et al. (2001) Antibody response to *Campylobacter* infections determined by an enzyme-linked immunosorbent assay: 2-year follow-up study of 210 patients. *Clinical and Vaccine Immunology* 8, 314–319. Available at http://cvi.asm.org/content/8/2/314.long.
20. Simonsen J et al. (2011) Usefulness of seroconversion rates for comparing infection pressures between countries. *Epidemiology and Infection* 139, 636–643.
21. Ang CW et al. (2011) Seroepidemiological studies indicate frequent and repeated exposure to *Campylobacter spp.* during childhood. *Epidemiology and Infection* 139, 1361–1368.